Study guide

13.3 Cushing's Syndrome: Aetiology, Screening & Localisation

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

13.3 Cushing's Syndrome: Aetiology, Screening & Localisation

Key Takeaways Explain This Topic AI

Failure of cortisol to suppress on overnight 1 mg dexamethasone is a screening result requiring confirmation, not a diagnosis, and is confounded by alcohol, depression and obesity.

Suppressed ACTH indicates an adrenal source; high ACTH with suppression on high-dose dexamethasone indicates pituitary Cushing's disease.

Ectopic ACTH from small cell lung cancer causes rapid onset with profound hypokalaemic alkalosis and pigmentation rather than classic cushingoid habitus.

Last updated: September 2026

The adrenal gland comprises an outer mesodermal cortex (zona glomerulosa producing mineralocorticoids, zona fasciculata producing glucocorticoids, and zona reticularis producing androgens) and an inner neural crest-derived medulla (chromaffin cells producing catecholamines). Understanding adrenal physiology, diagnostic suppression/stimulation testing, and hypertensive endocrinopathies is essential for MRCP(UK) Part 1.

  • 1. Cushing's Syndrome: Etiology, Screening & Localization
  • Classification & Pathophysiology

Cushing's syndrome describes the constellation of clinical features caused by prolonged, inappropriate systemic glucocorticoid excess:

Exogenous Glucocorticoids: By far the most prevalent cause overall. Characterized by bilateral adrenocortical atrophy, suppressed endogenous ACTH, and undetectable baseline cortisol.

Endogenous ACTH-Dependent (~80% of endogenous cases):

Cushing's Disease (~70%): ACTH-secreting pituitary adenoma (predominantly microadenomas < 10 mm < 10\text{ mm} < 10 mm ). More common in females (4:1 female-to-male ratio).

Ectopic ACTH Secretion (~10%): Non-pituitary neuroendocrine tumors. Most commonly small cell lung carcinoma (SCLC, ~50%) , bronchial carcinoid ( 10 – 15 % ~10\text{–}15\% 10 – 15% ), pancreatic neuroendocrine tumors, thymic tumors, or medullary thyroid carcinoma. Ectopic ACTH often presents rapidly with severe hypokalaemic metabolic alkalosis , profound proximal muscle wasting, hyperpigmentation, and cachexia, rather than classical centripetal obesity.

Ectopic CRH Secretion ( < 1 % < 1\% < 1% ): Extremely rare.

Endogenous ACTH-Independent (~20% of endogenous cases):

Adrenocortical Adenoma (~10–15%): Autonomous cortisol secretion from a unilateral benign adrenal tumor with contralateral cortical atrophy.

Adrenocortical Carcinoma (~5%): Highly aggressive malignant tumor, frequently co-secreting androgens (manifesting as rapid virilization, hirsutism, and severe abdominal mass effects).

Primary Pigmented Nodular Adrenocortical Disease (PPNAD / Carney Complex) and Bilateral Macronodular Adrenal Hyperplasia (BMAH) .

Clinical Features

Cardinal clinical signs with the highest discriminatory diagnostic value include proximal myopathy (severe muscle wasting, inability to climb stairs or stand from a squatting position), wide purple/violaceous striae ( > 1 cm > 1\text{ cm} > 1 cm width on abdomen, flanks, or breasts), facial plethoric mooning , dorsocervical fat pad ('buffalo hump') , supraclavicular fat pads, thin fragile skin with spontaneous ecchymoses/easy bruising, impaired wound healing, osteopenia/vertebral collapse, neuropsychiatric disturbances (depression, emotional lability, psychosis), systemic hypertension, and secondary type 2 diabetes.

Tiered Diagnostic Strategy

Establishing a diagnosis requires three sequential steps: (1) Confirm hypercortisolism, (2) Determine ACTH dependency, and (3) Localize the anatomical source.

Step 1: Confirming Glucocorticoid Excess (Screening)

At least two concordant positive screening tests are required to confirm Cushing's syndrome:

Overnight 1 mg Dexamethasone Suppression Test (ONDST): 1 mg dexamethasone orally at 23:00; serum cortisol measured at 08:00–09:00 the following morning. Diagnostic cut-off: Failure to suppress serum cortisol to < 50 nmol/L < 50\text{ nmol/L} < 50 nmol/L ( < 1.8 mcg/dL < 1.8\text{ mcg/dL} < 1.8 mcg/dL ) indicates autonomous cortisol production. (False positives occur with CYP3A4 inducers [phenytoin, carbamazepine, rifampicin], high oestrogen/pregnancy elevating cortisol-binding globulin, severe depression, obesity, and alcohol excess [pseudo-Cushing's]).

24-Hour Urinary Free Cortisol (UFC): Measures unbound cortisol filtered by the glomeruli over 24 hours. Requires at least 2–3 collections; levels > 3 × > 3 \times > 3 × the upper reference limit confirm hypercortisolism.

Late-Night Salivary Cortisol: Saliva collected at 23:00–24:00 using a cotton swab. Loss of the normal midnight physiological nadir is highly sensitive ( > 95 % > 95\% > 95% ).

Step 2: Differentiating ACTH Dependency

Morning plasma ACTH (measured on ice at 09:00):

Plasma ACTH < 10 pg/mL < 10\text{ pg/mL} < 10 pg/mL ( < 2 pmol/L < 2\text{ pmol/L} < 2 pmol/L ): ACTH-Independent. Autonomous adrenal secretion suppresses pituitary corticotrophs. Next step: High-resolution adrenal CT or MRI to identify an adrenal adenoma, carcinoma, or bilateral nodular hyperplasia.

Plasma ACTH ≥ 20 pg/mL \ge 20\text{ pg/mL} ≥ 20 pg/mL ( > 4.4 pmol/L > 4.4\text{ pmol/L} > 4.4 pmol/L ) (or inappropriately normal in the presence of hypercortisolism): ACTH-Dependent. Indicates either a pituitary corticotroph adenoma or ectopic ACTH secretion.

Step 3: Localizing ACTH-Dependent Sources

Distinguishing a pituitary adenoma from an ectopic neuroendocrine tumor:

High-Dose Dexamethasone Suppression Test (HDDST): 8 mg dexamethasone orally overnight (or 2 mg 6-hourly for 48 hours). Pituitary adenomas retain partial negative feedback: serum cortisol suppresses by > 50 % > 50\% > 50% of baseline . Ectopic ACTH tumors are fully autonomous: serum cortisol fails to suppress ( < 50 % < 50\% < 50% suppression) .

Corticotropin-Releasing Hormone (CRH) Test: 100 mcg IV human or ovine CRH. Pituitary adenomas express CRH receptors and respond with an exaggerated rise in ACTH ( > 50 % > 50\% > 50% ) and cortisol ( > 20 % > 20\% > 20% ) . Ectopic tumors lack functional CRH receptors and show no biochemical response.

Inferior Petrosal Sinus Sampling (IPSS): The gold standard diagnostic investigation for ACTH-dependent Cushing's when pituitary MRI is negative, indeterminate, or shows a microadenoma < 6 mm < 6\text{ mm} < 6 mm . Bilateral microcatheters sample ACTH simultaneously from the inferior petrosal sinuses (draining the pituitary) and a peripheral vein, before and after peripheral CRH administration:

Central-to-Peripheral ACTH Ratio: Baseline ratio > 2.0 > 2.0 > 2.0 , or post-CRH peak ratio > 3.0 > 3.0 > 3.0 , unequivocally confirms a pituitary source (Cushing's disease) .

Ratio < 2.0 < 2.0 < 2.0 at baseline and < 3.0 < 3.0 < 3.0 post-CRH indicates ectopic ACTH secretion , directing whole-body thoracic/abdominal CT, gallium-68 DOTATATE PET-CT, or octreoscan imaging.

Diagnostic Test Cushing's Disease (Pituitary) Ectopic ACTH Secretion Adrenal Adenoma / Carcinoma

Basal Plasma ACTH Elevated or inappropriately normal Markedly elevated ( > 100 pg/mL > 100\text{ pg/mL} > 100 pg/mL ) Completely suppressed ( < 10 pg/mL < 10\text{ pg/mL} < 10 pg/mL )

Overnight 1 mg DST Failure to suppress ( > 50 nmol/L > 50\text{ nmol/L} > 50 nmol/L ) Failure to suppress ( > 50 nmol/L > 50\text{ nmol/L} > 50 nmol/L ) Failure to suppress ( > 50 nmol/L > 50\text{ nmol/L} > 50 nmol/L )

High-Dose (8 mg) DST Suppresses by > 50 % > 50\% > 50% Fails to suppress ( < 50 % < 50\% < 50% ) Fails to suppress ( < 50 % < 50\% < 50% )

CRH Stimulation Test ACTH rises > 50 % > 50\% > 50% , cortisol > 20 % > 20\% > 20% No rise in ACTH or cortisol No rise in ACTH or cortisol

IPSS Petrosal:Peripheral > 2.0 > 2.0 > 2.0 basal; > 3.0 > 3.0 > 3.0 post-CRH < 2.0 < 2.0 < 2.0 basal; < 3.0 < 3.0 < 3.0 post-CRH Not indicated

Definitive Management Transsphenoidal hypophysectomy Tumor excision / Somatostatin analogues / Metyrapone Unilateral laparoscopic adrenalectomy